相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cisplatin Selects for Multidrug-Resistant CD133(+) Cells in Lung Adenocarcinoma by Activating Notch Signaling
Yu-Peng Liu et al.
CANCER RESEARCH (2013)
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy
Toshio Kubo et al.
CANCER SCIENCE (2013)
Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
Astrid A. M. van der Veldt et al.
CLINICAL CANCER RESEARCH (2013)
Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients
Derrek A. Heuveling et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
Khalid Abubaker et al.
MOLECULAR CANCER (2013)
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer
George D. Cimino et al.
BIOANALYSIS (2013)
A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human Cells
Kristin D. Ivy et al.
MOLECULAR PHARMACOLOGY (2013)
Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression
Junye Liu et al.
BMC CANCER (2012)
Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy
Macus Tien Kuo et al.
CANCER RESEARCH (2012)
Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing
Marie Croft et al.
CLINICAL PHARMACOKINETICS (2012)
Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Johnson J. Liu et al.
CURRENT CANCER DRUG TARGETS (2012)
Cellular senescence and cancer chemotherapy resistance
Ryan R. Gordon et al.
DRUG RESISTANCE UPDATES (2012)
Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer
Eric S. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Microdosing: A critical assessment of human data
Malcolm Rowland
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Purification and biochemical characterization of a novel protein-tongue cancer chemotherapy resistance-associated protein1 (TCRP1)
Bo Peng et al.
PROTEIN EXPRESSION AND PURIFICATION (2012)
Comparative requirements for exploratory clinical trials - eIND, eCTA and microdosing
Patrick Y. Muller
ADVANCED DRUG DELIVERY REVIEWS (2011)
Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer
Xi Xia et al.
BMC CANCER (2011)
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma
M. Yamasaki et al.
BRITISH JOURNAL OF CANCER (2011)
A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance
Paul T. Henderson et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non-Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy
Li-E Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway
Yixue Gu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells
Yu-Han Shen et al.
TOXICOLOGY LETTERS (2011)
Genetic modifiers of carcinogen DNA adducts in target lung and peripheral blood mononuclear cells
Mi-Sun Lee et al.
CARCINOGENESIS (2010)
The therapeutic promise of the cancer stem cell concept
Natasha Y. Frank et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Human microdosing for the prediction of patient response
Paul T. Henderson et al.
BIOANALYSIS (2010)
Microdosing: current and the future
Graham Lappin
BIOANALYSIS (2010)
A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin
Ken Andre Olaussen
CANCER BIOLOGY & THERAPY (2009)
Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model
Walid Fayad et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through Its Death Receptors in MDA-MB-231 Breast Cancer Cells
Tatsushi Yoshida et al.
MOLECULAR CANCER RESEARCH (2009)
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Manuela Santarosa et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
Shuji Ota et al.
LUNG CANCER (2009)
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
Giulia Bertolini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
High-performance liquid chromatography accelerator mass spectrometry: Correcting for losses during analysis by internal standardization
G. Lappin et al.
ANALYTICAL BIOCHEMISTRY (2008)
Subattomole sensitivity in biological accelerator mass spectrometry
Mehran Salehpour et al.
ANALYTICAL CHEMISTRY (2008)
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy
Matthew D. Hall et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
The utility of microdosing over the past 5 years
Graham Lappin et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes
A. Saleem et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Identification and expansion of the tumorigenic lung cancer stem cell population
A. Eramo et al.
CELL DEATH AND DIFFERENTIATION (2008)
Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death
Seung-Chul Choi et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2007)
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
Anders Lorentzen et al.
BMC CANCER (2007)
Tumorigenic stem and progenitor cells: Implications for the therapeutic index of anti-cancer agents
Vera S. Donnenberg et al.
JOURNAL OF CONTROLLED RELEASE (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA
Maria Berndtsson et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
Alison K. Holzer et al.
MOLECULAR PHARMACOLOGY (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Ken A. Olaussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: A review
P Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker
T Hirano et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma
EA Lusis et al.
CANCER RESEARCH (2005)
Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: Implications for treatment response
LW Elmore et al.
CLINICAL CANCER RESEARCH (2005)
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer
K Yoh et al.
CLINICAL CANCER RESEARCH (2004)
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells
G Samimi et al.
CLINICAL CANCER RESEARCH (2004)
The role of copper transporters in the development of resistance to Pt drugs
R Safaei et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2004)
Reversal of human cellular senescence:: roles of the p53 and p16 pathways
CM Beauséjour et al.
EMBO JOURNAL (2003)
Reversal of senescence in mouse fibroblasts through lentiviral in suppression of p53
AMG Dirac et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients
L Medina-Gundrum et al.
ANTI-CANCER DRUGS (2003)
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
S Ishida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias
JF Beck et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
DNA damage recognition and nucleotide excision repair in mammalian cells
RD Wood et al.
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY (2000)
分享论文
